Cargando…
Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 v...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661836/ https://www.ncbi.nlm.nih.gov/pubmed/23704674 http://dx.doi.org/10.2337/dc12-2393 |
Ejemplares similares
-
Comment on: TODAY Study Group. Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care 2013;36:1749–1757
por: Baldi, James C., et al.
Publicado: (2013) -
Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010) -
Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
por: Kahn, Steven E., et al.
Publicado: (2011) -
A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
por: Tandon, Tanya, et al.
Publicado: (2019) -
Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
por: Dormuth, Colin R., et al.
Publicado: (2009)